Jai P. Singh
FDA investigator
Appears on 2 documents from 2016 to 2020, mostly at sites in Maryland. Most often cites testing and release for distribution (21 CFR 211.165).
- 2
- Documents on file
- 4.5
- Observations per 483
- 2016
- First seen
- 2020
- Most recent
What they cite most
From 9 observations- 21 CFR 211.165Testing and release for distribution2
- 21 CFR 211.110Sampling and testing of in-process materials and drug products1
- 21 CFR 211.113Control of microbiological contamination1
- 21 CFR 211.167Special testing requirements1
- 21 CFR 211.42Design and construction features1
- 21 CFR 211.65Equipment construction1
Activity by year
2016: 1, 2020: 1
Where
Maryland 2
Often inspects with
Is Jai P. Singh coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
2 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2020-05-23 | 483 MedPark PharmacyMay 23, 2020 · Annapolis, Maryland | Annapolis, Maryland | 5 | |
| 2016-05-06 | 483 Arnold Professional PharmacyMay 6, 2016 · Arnold, Maryland | Arnold, Maryland | 4 |
About this profile
What does Jai P. Singh inspect?
Jai P. Singh appears on 2 documents on file covering 2 sites, mostly in Maryland.
What do they cite most often?
21 CFR 211.165 (testing and release for distribution), followed by 21 CFR 211.110 and 21 CFR 211.113.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Jai P. Singh is dated May 23, 2020.